$18.9M Biogen Securities Settlement, Check If You Qualify, File by Sept. 24 — Oklahoma Firefighters Pension and Retirement System v. Biogen Inc., No. 22-cv-10200

There’s $18,900,000 waiting for eligible investors — if you bought Biogen common stock between June 8, 2021, and July 12, 2021. Biogen Inc. agreed to pay the full amount to settle claims that it misled shareholders about Medicare coverage for its Alzheimer’s drug Aduhelm. You have until September 24, 2026, to file.

Biogen Securities Settlement — Key Facts

Settlement Amount	$18,900,000
Claim Deadline	September 24, 2026
Who Qualifies	All persons and entities who purchased or otherwise acquired Biogen common stock between June 8, 2021, and July 12, 2021, inclusive
Estimated Payout	Approximately $1.36 per share before fees and expenses are deducted, per Lead Plaintiff’s damages expert. Actual recovery depends on when you bought and sold, and on the Plan of Allocation formula — this is an estimate, not a guarantee.
Proof Required	Yes — brokerage statements, trade confirmations, or a signed broker letter documenting your Biogen transactions
Settlement Status	Notice issued June 16, 2026; awaiting Final Approval at the Settlement Hearing
Court & Case Number	U.S. District Court, District of Massachusetts — No. 22-cv-10200-WGY
Law Alleged	Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, Rule 10b-5
Administrator	Strategic Claims Services
Official Claim Site	biogensecuritieslitigation.com
Last Updated	July 10, 2026

Who Is Biogen and Why Are They Being Sued Over Aduhelm Statements?

Biogen is a biotechnology company that develops treatments for chronic neurological diseases. On June 7, 2021, the FDA granted accelerated approval for Aduhelm, the first FDA-approved treatment aimed at slowing Alzheimer’s disease progression — a genuine milestone that sent expectations, and the stock price, soaring. The very next day, on an investor call, Biogen executives made statements about insurance coverage that plaintiffs say weren’t true.

What Did Biogen Do to Investors on June 8, 2021?

Lead Plaintiff Oklahoma Firefighters Pension and Retirement System alleges that then-CEO Michel Vounatsos told investors the company “engaged with stakeholders, including payers” in setting Aduhelm’s price. When an analyst asked what insurers might do to limit access, then-executive Alisha Alaimo said Medicare fee-for-service coverage was “automatically presumed” with FDA approval.

Neither statement held up. Corrective information reached the market on June 24, 2021, and again on July 15, 2021, and Biogen’s stock price dropped both times. The case took years to get here — dismissed in 2023, reopened in 2024, class-certified that September, appealed to the First Circuit, and headed toward trial before the parties reached a settlement one month before jury selection was set to begin.

Related coverage: our article on the Biogen/Eisai adverse event reporting issues tracks other regulatory scrutiny facing the company’s neurology drug pipeline, if you’re following Biogen litigation more broadly. [Skip this link if no genuinely relevant Biogen article exists on your site — flagging rather than forcing.]

Who Qualifies for the Biogen Securities Settlement?

Here’s exactly how to know if this case includes you.

• Anyone who purchased or otherwise acquired Biogen common stock between June 8, 2021, and July 12, 2021
• Investors who held shares through this window, even without selling
• Institutional and individual investors alike — there’s no minimum share requirement
• Anyone who bought through a brokerage account, retirement account outside an ERISA plan, or direct purchase

You do not qualify if your only Biogen holdings were purchased before June 8, 2021, and sold before that date, or if your shares were held exclusively inside an ERISA plan (those claims must be filed by the plan’s trustees, not individual participants). Option contracts on Biogen stock are also excluded — only common stock counts.

Related article: Aidvantage Robocall $3M TCPA Settlement, Check If You Qualify, Deadline Aug. 24, 2026 Knox v. Maximus Education, LLC, dba Aidvantage, No. 2:25-cv-00121

Biogen Investors Outside Massachusetts — Are You Still Covered?

Yes. This is a federal securities class action, so it covers investors nationwide regardless of where you live. Your eligibility depends only on when you bought or sold Biogen stock, not your location.

Not sure if you qualify for the Biogen securities settlement? A free consultation with a securities fraud attorney can help you work through the transaction math before the September 24 deadline.

How Much Can Biogen Settlement Class Members Get? Up to Approximately $1.36 Per Share

The Net Settlement Fund — what’s left of the $18.9 million after attorneys’ fees, litigation costs, and administration expenses — gets divided among everyone who files a valid claim, based on a formula tied to when you bought and sold relative to the two corrective disclosures.

Lead Counsel is asking the court for up to one-third of the settlement fund in fees, plus up to $1,500,000 in litigation expenses. That’s normal in cases like this — the attorneys took the case on full contingency and haven’t been paid a cent through years of litigation, including an appeal.

Here’s an honest number worth sitting with: the estimated average recovery is about $1.36 per share, before those fees come out. If you only bought a handful of shares, your actual payout could be modest. If your Distribution Amount calculates to less than $10, you won’t receive a separate payment — that amount rolls into other claimants’ shares instead.

Why Proof of Purchase Actually Matters Here

Unlike some settlements where the company already has your data, Biogen and the court have no record of your personal trading history. You have to supply your own brokerage statements or trade confirmations. Skip this step and your claim gets rejected, no matter how many shares you actually held.

How to File Your Biogen Settlement Claim — Step by Step

1. Go to the official site: biogensecuritieslitigation.com
2. Complete the Proof of Claim and Release form with your name, address, and account details
3. List every Biogen purchase, acquisition, and sale between June 8, 2021, and October 12, 2021 — not just the class period, since the formula tracks your full holding pattern
4. Attach documentation: brokerage statements, trade confirmation slips, or a signed broker letter
5. Sign the certification section and submit online or by mail
6. Save your confirmation — postmark or online submission must land by September 24, 2026

Estimated time: 20 to 30 minutes if you have your brokerage records handy, longer if you need to track them down first.

⚠️ 76 days left as of today — start gathering records now if you haven’t already.

Should Biogen Class Members Opt Out or Object Before Their Deadlines?

What Opting Out of the Biogen Settlement Actually Means

Opting out means no payment from this fund, but it preserves your right to sue Biogen individually over the same statements. Most investors with modest holdings have little reason to opt out, since individual securities litigation is expensive and slow. If your losses were substantial, talk to a securities attorney before deciding. The opt-out deadline is August 25, 2026 — earlier than the claim filing deadline.

How to Object to the Biogen Settlement

You can stay in the class and still tell the court you disagree with the settlement terms, the Plan of Allocation, or the requested attorneys’ fees. Objections must be filed in writing with the Clerk’s Office, U.S. District Court for the District of Massachusetts, 1 Courthouse Way, Ste. 2300, Boston, MA 02210, and must include documentation of your Biogen transactions. The objection deadline is September 8, 2026.

Talk to a class action securities lawyer before your relevant deadline if you’re considering either option.

Biogen Securities Settlement — Key Dates, 2026

Milestone	Date
Notice Issued	June 16, 2026
Opt-Out Deadline	August 25, 2026
Objection Deadline	September 8, 2026
Claim Filing Deadline	September 24, 2026
Final Settlement Hearing	September 29, 2026, 2:00 p.m.
Expected Payment Date	UNVERIFIED — distribution occurs after final approval and resolution of any appeals; no specific date set

Biogen Securities — Frequently Asked Questions, No. 22-cv-10200

Do I need a lawyer to file a Biogen settlement claim?

 No. You can file directly at biogensecuritieslitigation.com without hiring an attorney, though the process requires gathering your own trading documentation.

Is the Biogen securities settlement legitimate?

 Yes. It’s supervised by the U.S. District Court for the District of Massachusetts, with Strategic Claims Services as the court-approved administrator.

When will Biogen settlement payments be sent?

 Not yet scheduled. Distribution happens only after the September 29, 2026 hearing, final court approval, and resolution of any appeals — a process the notice itself says can take time.

What if I missed the September 24 deadline?

 You’d be barred from any payment but would still be bound by the settlement’s release of claims, whether or not you filed. There’s no exception described in the notice for late filers.

Do I need to prove every single trade, even the profitable ones?

 Yes. The claim form requires all your purchases, acquisitions, and sales during the broader period, not just losing trades — the formula needs your complete picture to calculate net loss.

What specific law does Biogen allegedly violate? 

Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5, which prohibit materially false or misleading statements made in connection with the purchase or sale of securities.

How much could Biogen investors get if this settles?

 An estimated $1.36 per affected share before fees, though your actual Recognized Loss Amount depends on exact purchase and sale dates under the court’s Plan of Allocation.

Sources Used in This Biogen Article

• Notice of Proposed Settlement of Class Action and Proof of Claim and Release — Oklahoma Firefighters Pension and Retirement System v. Biogen Inc., et al., No. 1:22-cv-10200-WGY, issued June 16, 2026: https://biogensecuritieslitigation.com/wp-content/uploads/sites/21/2026/06/Notice-of-Proposed-Settlement-of-Class-Action-and-Proof-of-Claim-and-Release-1.pdf
• Official Settlement Website: https://biogensecuritieslitigation.com/

This article is for informational purposes only and does not constitute legal advice. Laws vary by state and individual circumstances differ. For advice about your specific situation, consult a qualified attorney.